1,176 Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX) Bought by Lee Danner & Bass Inc.

Lee Danner & Bass Inc. acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,176 shares of the company’s stock, valued at approximately $486,000.

Other hedge funds have also added to or reduced their stakes in the company. FSA Wealth Management LLC bought a new position in IDEXX Laboratories during the 3rd quarter worth about $25,000. Rialto Wealth Management LLC bought a new position in IDEXX Laboratories during the 4th quarter worth about $30,000. Retirement Wealth Solutions LLC bought a new position in IDEXX Laboratories during the 4th quarter worth about $31,000. Kestra Investment Management LLC bought a new position in IDEXX Laboratories during the 4th quarter worth about $38,000. Finally, Crews Bank & Trust bought a new position in IDEXX Laboratories during the 4th quarter worth about $41,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 0.1 %

Shares of IDXX stock opened at $420.99 on Friday. The firm has a 50 day moving average price of $437.36 and a two-hundred day moving average price of $445.11. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $34.24 billion, a PE ratio of 39.46, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $548.88.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.11% of the company’s stock.

Analysts Set New Price Targets

IDXX has been the subject of a number of research reports. Leerink Partners initiated coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price for the company. Bank of America raised their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, March 15th. Morgan Stanley decreased their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Finally, Barclays raised their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.